Wellington Management Group
CBIO

Wellington Management Group’s Crescent Biopharma CBIO Stock Holding History

Wellington Management Group’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-143,412
Closed -$1.63M – 1930
2025
Q4 		$1.63M Buy
143,412
+125,714
+710% +$1.6M ﹤0.01% 1641
2025
Q3 		$210K Sell
17,698
-162,188
-90% -$2.15M ﹤0.01% 1943
2025
Q2 		$2.9M Buy
179,886
+166,183
+1,213% +$3.52M ﹤0.01% 1495
2025
Q1 		$288K Sell
13,703
-431
-3% -$11.5K ﹤0.01% 1878
2024
Q4 		$352K Buy
+14,134
New +$385K ﹤0.01% 1865
2020
Q4 		– Sell
-36,773
Closed -$11.3M – 1953
2020
Q3 		$11.3M Sell
36,773
-8,811
-19% -$3.37M ﹤0.01% 1076
2020
Q2 		$17.1M Sell
45,584
-2,735
-6% -$774K ﹤0.01% 957
2020
Q1 		$11M Buy
48,319
+11,259
+30% +$4.3M ﹤0.01% 1016
2019
Q4 		$19.6M Sell
37,060
-1,513
-4% -$819K ﹤0.01% 999
2019
Q3 		$16.6M Sell
38,573
-9,050
-19% -$5.82M ﹤0.01% 1017
2019
Q2 		$56.8M Sell
47,623
-2,024
-4% -$2.42M 0.01% 719
2019
Q1 		$61.9M Sell
49,647
-3,546
-7% -$4.06M 0.01% 681
2018
Q4 		$50.4M Sell
53,193
-3,541
-6% -$4.26M 0.01% 705
2018
Q3 		$81.7M Buy
56,734
+810
+1% +$1.23M 0.02% 651
2018
Q2 		$90.2M Sell
55,924
-1,951
-3% -$3.35M 0.02% 605
2018
Q1 		$93.9M Buy
57,875
+22,091
+62% +$45.9M 0.02% 591
2017
Q4 		$60.1M Buy
35,784
+835
+2% +$1.1M 0.01% 716
2017
Q3 		$48.9M Buy
34,949
+444
+1% +$521K 0.01% 760
2017
Q2 		$38.5M Buy
34,505
+2,337
+7% +$1.93M 0.01% 811
2017
Q1 		$17.5M Buy
32,168
+4,169
+15% +$2.56M ﹤0.01% 1082
2016
Q4 		$17.1M Buy
27,999
+371
+1% +$231K ﹤0.01% 1052
2016
Q3 		$19.8M Buy
27,628
+525
+2% +$402K ﹤0.01% 987
2016
Q2 		$19.7M Buy
27,103
+413
+2% +$285K 0.01% 951
2016
Q1 		$15.9M Buy
26,690
+436
+2% +$224K ﹤0.01% 999
2015
Q4 		$15M Buy
26,254
+27
+0.1% +$17.9K ﹤0.01% 1048
2015
Q3 		$14.7M Buy
26,227
+27
+0.1% +$19.5K ﹤0.01% 1058
2015
Q2 		$20.8M Buy
26,200
+6
+0% +$4.96K 0.01% 1008
2015
Q1 		$21.8M Buy
26,194
+204
+0.8% +$158K 0.01% 1014
2014
Q4 		$18.7M Sell
25,990
-64
-0.2% -$50.1K ﹤0.01% 1067
2014
Q3 		$18.1M Buy
26,054
+1,962
+8% +$1.59M 0.01% 1059
2014
Q2 		$20.3M Sell
24,092
-372
-2% -$370K 0.01% 1031
2014
Q1 		$40M Buy
+24,464
New +$29.6M 0.01% 816

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group's CBIO Position: Q1 2026 in Review

Wellington Management Group sold out of Crescent Biopharma (CBIO) in Q1 2026, closing a stake of 143,412 shares — an estimated $1.63M sold.

Wellington Management Group first reported a position in CBIO in Q1 2014 and held it in 32 quarters. The position peaked at $93.9M in Q1 2018. 63 funds tracked by Wall St. Rank hold CBIO as of Q1 2026.

  • Wellington Management Group reported no remaining Crescent Biopharma position as of Q1 2026 after selling out during the quarter.
  • Wellington Management Group sold 143,412 Crescent Biopharma shares in Q1 2026, an estimated $1.63M.
  • Wellington Management Group first reported a position in Crescent Biopharma in Q1 2014 and held it in 32 quarters.
  • Wellington Management Group's Crescent Biopharma position peaked at $93.9M in Q1 2018.
  • 63 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2026.

Based on Wellington Management Group's 13F filing for Q1 2026, filed 15 May 2026.